We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Infrared Signature for Mobile Phone Detects Malaria

By LabMedica International staff writers
Posted on 13 Dec 2022
Print article
Image: The malaria detection tool collects an infrared signature for a mobile phone to process (Photo courtesy of The University of Queensland)
Image: The malaria detection tool collects an infrared signature for a mobile phone to process (Photo courtesy of The University of Queensland)

Optical microscopy, rapid diagnostic tests (RDTs) and molecular tests are the three main diagnostic techniques currently available for malaria diagnosis. Microscopy is the traditional way of detecting malaria parasites in stained thick or thin peripheral blood films using Giemsa, Wrights or Fields stains.

RDTs detect malaria antigens in blood by targeting falciparum-specific protein such as histidine-rich protein II (HRP-II) or lactate dehydrogenase (LDH). RDTs are simple, relatively cheap and can be used in remote areas without specialized equipment or need for electricity. However, RDTs can only reliably detect 50-100 parasites/ µL. Molecular tests such as polymerase chain reaction (PCR) are currently the most accurate and the most sensitive techniques for detecting malaria in low or sub-microscopic samples, for mixed infections and for differentiating Plasmodium species.

An international team of Tropical Medicine Specialists aided by those at The University of Queensland (Brisbane, Australia) hypothesized that the presence of malaria parasites in red blood cells produce unique infrared signatures that could potentially be used for malaria detection. They used a handheld near infrared spectrometer reflective (NIRS) model to non-invasively collect spectral signatures from the right and left ears, arms and fingers of malaria positive and negative individuals living in a malaria endemic area in Brazil where both P. falciparum and P. vivax are prevalent at a 30%/70% ratio. A total of 60 patients were scanned and a total of 360 spectra were collected. The infection status and Plasmodium species type were confirmed by microscopy and standard PCR.

The scientists uses the NIRvascan NIRS model G1 (Allied Scientific Pro, Gatineau, QC . Canada). The model used is a diffuse reflectance spectrometer with wavelength ranging from 900-1700nm, a 5000:1 signal to noise ratio and an optical resolution of 10nm pixel resolution. It has an inGaAs detector (Hamamatsu Photonics, Herrsching Germany), and it weighs 136g and measures 82.2 × 63× 40 mm, it is rechargeable and can be operated by either a computer or a smart-phone via Bluetooth.

The investigators reported that results from PCR confirmed 27/60 (45%) people scanned were positive with malaria while the rest were malaria negative. Of the malaria positive individuals, 75% (N=20) and 25% (N=7), were infected with P. vivax and P. falciparum, respectively. Results from microscopy indicated that out of the 27 infected patients, 7.4% (two subjects) had extremely high parasitaemia, 18.5% (five subjects) had moderate parasitaemia, 44.4% (12 subjects) had low parasitaemia and 29.6% (eight subjects) had very low parasitaemia.

Spectra collected from the ear produced the most accurate prediction of infection in the independent subjects with an accuracy of 92% (N=24), sensitivity of 100% (N=11) and specificity of 85% (N=13). Comparatively, the accuracy, sensitivity and specificity of the spectra collected from the finger was 70% (N=24), 72 (N=11) and 69% (N=13), respectively whereas spectra of the arm resulted into a predictive accuracy of 72% (N=24), sensitivity of 59% (N=11) and specificity of 85% (N=13).

The authors concluded that their proof-of-concept study provides insights on the potential application of NIRS and machine learning techniques for rapid, non-invasive and large-scale surveillance of malaria and potentially other human pathogens. The study was published on December 7, 2022 in the journal PNAS Nexus.

Related Links:
The University of Queensland 
Allied Scientific Pro
Hamamatsu Photonics

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.